0.00
전일 마감가:
$0.2001
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$13.94M
수익:
-
순이익/손실:
$-52.53M
주가수익비율:
0.00
EPS:
-3.66
순현금흐름:
$-39.93M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
Unity Biotechnology Inc Stock (UBX) Company Profile
명칭
Unity Biotechnology Inc
전화
(650) 416-1192
주소
285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA
UBX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
UBX
Unity Biotechnology Inc
|
0.00 | 13.94M | 0 | -52.53M | -39.93M | -3.66 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
467.46 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
557.53 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
326.35 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
596.76 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
305.50 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Unity Biotechnology Inc Stock (UBX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-05-27 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
2025-05-16 | 다운그레이드 | Mizuho | Outperform → Neutral |
2024-08-22 | 개시 | Rodman & Renshaw | Buy |
2023-11-16 | 업그레이드 | Wedbush | Neutral → Outperform |
2022-01-04 | 업그레이드 | ROTH Capital | Neutral → Buy |
2021-11-10 | 업그레이드 | Mizuho | Neutral → Buy |
2021-06-28 | 업그레이드 | Citigroup | Sell → Buy |
2021-06-07 | 개시 | H.C. Wainwright | Buy |
2021-02-16 | 다운그레이드 | Citigroup | Neutral → Sell |
2020-08-18 | 다운그레이드 | Citigroup | Buy → Neutral |
2020-08-18 | 다운그레이드 | Mizuho | Buy → Neutral |
2020-08-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2020-08-17 | 다운그레이드 | ROTH Capital | Buy → Neutral |
2020-07-28 | 개시 | ROTH Capital | Buy |
2019-12-12 | 개시 | Cantor Fitzgerald | Overweight |
2019-03-07 | 개시 | Cantor Fitzgerald | Overweight |
2018-09-07 | 개시 | Mizuho | Buy |
2018-05-29 | 개시 | Citigroup | Buy |
2018-05-29 | 개시 | Goldman | Neutral |
2018-05-29 | 개시 | Morgan Stanley | Overweight |
모두보기
Unity Biotechnology Inc 주식(UBX)의 최신 뉴스
How to use a screener to detect Unity Biotechnology Inc. breakoutsVolume Based Swing Signal Prediction Map - Newser
What makes Unity Biotechnology Inc. stock price move sharplyReal-Time Signal Tracking with Entry Level - Newser
What are the latest earnings results for Unity Biotechnology Inc.Game-changing capital returns - jammulinksnews.com
When is Unity Biotechnology Inc. stock expected to show significant growthGet professional guidance for market timing - jammulinksnews.com
Real time social sentiment graph for Unity Biotechnology Inc. Safe Investment Ideas with Growth Upside - Newser
How does Unity Biotechnology Inc. compare to its industry peersBreakout portfolio performance - jammulinksnews.com
What catalysts could drive Unity Biotechnology Inc. stock higher in 2025Invest smarter with expert stock recommendations - jammulinksnews.com
Sectors Driving Future Growth for Unity Biotechnology Inc. StockFree Expert-Led Investment Training - Newser
How many analysts rate Unity Biotechnology Inc. as a “Buy”Sky-high return potential - jammulinksnews.com
Is Unity Biotechnology Inc. stock overvalued or undervaluedFree Expert Stock Watchlist - jammulinksnews.com
What drives Unity Biotechnology Inc. stock priceHigh-octane gains - PrintWeekIndia
Unity Biotechnology Inc. Stock Analysis and ForecastTriple-digit profit margins - PrintWeekIndia
Published on: 2025-07-25 18:10:37 - Autocar Professional
Why Unity Biotechnology Inc. stock attracts strong analyst attentionHigh Potential Safe Trades - Newser
What analysts say about Unity Biotechnology Inc. stockOverwhelming financial success - PrintWeekIndia
UBX issues 1 share with 600M votes to speed dissolution plan | UBX SEC FilingForm 8-K/A - Stock Titan
Is Unity Biotechnology Inc. a good long term investmentAccelerated wealth building - Autocar Professional
Unity Biotechnology Alters Voting Dynamics with New Stock - TipRanks
How Unity Biotechnology Inc. stock performs during market volatilityFree Stock Movement Tracking - Newser
Diabetic Macular Edema Pipeline 2025: MOA, ROA, FDA-Approved Drugs, And Clinical Trial Progress Assessment By Delveinsight Oxurion, Ocuphire Pharma, YD Life Science, Unity Biotechnology, Novartis - MenaFN
Diabetic Macular Edema Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Oxurion, Ocuphire Pharma, YD Life Science, Unity Biotechnology, Novartis - The Globe and Mail
Unity Biotechnology, Inc.(NasdaqGS: UBX) dropped from S&P TMI Index - MarketScreener
New Options Listings and Delistings for July 9th: DTCBD, ECG, EMA, UNBX, DTCB, AKYA, UBX - AInvest
Unity Biotechnology Inc (UBX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):